Armed with $137M fund, Signet launch­es hunt for a dozen new biotech plays

Signet Health­care Part­ners is get­ting the year start­ed by rolling out a new, $137 mil­lion biotech fund.

The New York-based group won’t win any awards for the biggest fund to hit the in­dus­try as VCs make off with a string of record sums. But it’s now lin­ing up about a dozen new port­fo­lio plays.

The 19-year-old fund has ac­cu­mu­lat­ed a large port­fo­lio over the years, in­vest­ing in firms like Pfenex, one of 45 up­starts they’ve backed with more than $400 mil­lion. And they’re look­ing to in­vest up to $15 mil­lion in each new com­pa­ny they back.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER